

## Oncology Today with Dr Neil Love: Key Abstracts in Head, Neck and Thyroid Cancers from the 2022 ASCO Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following results was reported with pembrolizumab in combination with cabozantinib at ASCO 2022 from a Phase II trial for patients with inoperable, refractory or metastatic head and neck cancer?
  - An overall response rate >50%
  - An overall response rate <50%
- In the Phase III ConCERT trial of standard versus lower-dose chemotherapy in combination with radiation therapy for locally advanced head and neck cancer, which of the following Grade III and IV toxicities was significantly less common with the lower dose?
  - Ototoxicity
  - Mucositis
  - Diarrhea
  - Dermal reactions
- Patients with which histologic subtype of radioactive iodine-refractory differentiated thyroid cancer who experienced disease progression after therapy with a VEGF inhibitor derived a progression-free survival benefit with cabozantinib in a trial comparing that agent to placebo?
  - Papillary thyroid cancer
  - Follicular thyroid cancer
  - Papillary or follicular thyroid cancer
- Which of the following genomic alterations was the most frequently observed in the circulating cell-free tumor DNA of patients with thyroid cancer using next-generation sequencing in a trial reported by investigators from the Moffitt Cancer Center at ASCO 2022?
  - BRAF mutation
  - RET fusion
  - ALK fusion
  - NTRK fusion
- At ASCO 2022, which of the following outcomes was reported with the addition of avasopasem versus placebo to radiation therapy for oral tumors in the ROMAN trial?
  - No significant difference in the incidence of mucositis
  - A significant increase in the incidence of mucositis with avasopasem
  - A significant reduction in the incidence of mucositis with avasopasem